Pharma BD Deal Intelligence

Pfizer Inc. / King Pharmaceuticals Inc.

2010 · Acquisition/Merger · $3.6B · Complete

Pfizer acquired King Pharmaceuticals for $3.6 billion in cash ($14.25 per share), a 40% premium to King's closing price. The deal bolstered Pfizer's pain management portfolio with abuse-deterrent formulations ahead of the Lipitor patent expiration.

Key facts

• Announced Oct 12, 2010
• Closed Feb 28, 2011
• Deal value $3.6B
• Deal type Acquisition/Merger
• Therapeutic area Neurology
• Indications Chronic Pain, Acute Pain
• Key assets Embeda (morphine sulfate/naltrexone), Flector Patch (diclofenac epolamine), Avinza (morphine sulfate ER)
• Mechanism Opioid agonist/antagonist combination, NSAID topical

← Browse all deals  ·  How we score deals